Low adiponectin drives insulin resistance and fatty liver.

Adiponectin is a protein hormone secreted by adipose tissue that plays a central role in regulating glucose levels and fatty acid breakdown. Research consistently identifies low levels of this hormone—hypoadiponectinemia—as a critical biomarker and driver for metabolic dysfunction, particularly in the liver and peripheral tissues.

Clinical and effectiveness evidence

• Insulin Resistance (IR): Clinical data demonstrates a strong inverse relationship between serum adiponectin and insulin resistance. Genetically elevated levels are causally linked to increased insulin sensitivity (β = 0.47–0.81). Conversely, low levels are consistently associated with higher HOMA-IR scores in diabetic populations. While some elderly, non-obese cohorts show variations in this pattern, the broad consensus supports adiponectin deficiency as a primary indicator of metabolic dysfunction.
• NAFLD/MASLD: Adiponectin levels are progressively lower as liver pathology advances from simple steatosis to nonalcoholic steatohepatitis (NASH) and significant fibrosis. Longitudinal studies show that adiponectin has superior predictive performance among metabolic biomarkers for identifying steatotic liver disease compared to other adipokines.

Mechanistic explanations

• AMPK Pathway: Adiponectin binds to AdipoR1 and AdipoR2 receptors, activating the AMP-activated protein kinase (AMPK) pathway. This stimulates glucose uptake and fatty acid oxidation. In cases of low adiponectin, impaired AMPK phosphorylation reduces mitochondrial β-oxidation, leading to ectopic lipid accumulation.
• Hepatoprotective Signaling: Adiponectin normally exerts anti-inflammatory effects in the liver. Low levels allow pro-inflammatory cytokines like TNF-α to dominate, which downregulates insulin receptor substrate-1 (IRS-1) and AKT activation, exacerbating both hepatic insulin resistance and fibrosis.

Bottom line

Low adiponectin is a scientifically validated biomarker for both insulin resistance and NAFLD, functioning through the impairment of AMPK signaling and the subsequent loss of protective lipid-oxidation and anti-inflammatory pathways.